Bristol-Myers Squibb (NYSE:BMY) Shares Up 0.2%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) was up 0.2% during mid-day trading on Wednesday . The stock traded as high as $45.17 and last traded at $44.81. 2,231,178 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 15,419,646 shares. The stock had previously closed at $44.71.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BMY. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a research note on Thursday, April 18th. Societe Generale downgraded Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a report on Monday, March 11th. Finally, BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating for the company in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $60.00.

Bristol-Myers Squibb Price Performance

The company has a market cap of $90.31 billion, a price-to-earnings ratio of -14.45, a P/E/G ratio of 15.23 and a beta of 0.45. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The business has a 50-day moving average price of $49.46 and a 200 day moving average price of $50.13.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb's revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.05 earnings per share. As a group, research analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.39%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb's payout ratio is -77.42%.

Institutional Investors Weigh In On Bristol-Myers Squibb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMY. Community Bank & Trust Waco Texas bought a new position in Bristol-Myers Squibb during the third quarter valued at approximately $168,000. Triumph Capital Management raised its holdings in shares of Bristol-Myers Squibb by 39.4% during the 3rd quarter. Triumph Capital Management now owns 5,182 shares of the biopharmaceutical company's stock valued at $301,000 after purchasing an additional 1,464 shares in the last quarter. Tower View Wealth Management LLC lifted its stake in shares of Bristol-Myers Squibb by 7.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 3,143 shares of the biopharmaceutical company's stock valued at $182,000 after purchasing an additional 215 shares during the last quarter. Allworth Financial LP lifted its holdings in Bristol-Myers Squibb by 5.5% in the 3rd quarter. Allworth Financial LP now owns 34,127 shares of the biopharmaceutical company's stock worth $1,981,000 after purchasing an additional 1,765 shares during the last quarter. Finally, Tilson Financial Group Inc. acquired a new position in Bristol-Myers Squibb during the third quarter valued at approximately $350,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.